0001104659-19-037459.txt : 20190625 0001104659-19-037459.hdr.sgml : 20190625 20190625180521 ACCESSION NUMBER: 0001104659-19-037459 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190624 FILED AS OF DATE: 20190625 DATE AS OF CHANGE: 20190625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Venture Capital VI, L.P. CENTRAL INDEX KEY: 0001687880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 19919553 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 a4.xml 4 X0306 4 2019-06-24 0 0001744659 Akero Therapeutics, Inc. AKRO 0001687880 Versant Venture Capital VI, L.P. C/O AKERO THERAPEUTICS, INC. 170 HARBOR WAY, 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 0 0 1 0 Common Stock 2019-06-24 4 C 0 3469759 A 3469759 D Common Stock 2019-06-24 4 C 0 235099 A 3704858 D Common Stock 2019-06-24 4 P 0 400000 16 A 4104858 D Series A Preferred Stock 2019-06-24 4 C 0 10666667 0 D Common Stock 3469759 0 D Series B Preferred Stock 2019-06-24 4 C 0 722737 0 D Common Stock 235099 0 D Represents the total number of shares of common stock received by Versant Venture Capital VI, L.P. ("Versant VI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. Represents the total number of shares of common stock received by Versant VI upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. These shares are owned directly by Versant VI. Versant Ventures VI GP, LP ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI. On June 24, 2019, Versant VI purchased 400,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC /s/ Robin L. Praeger, Managing Director 2019-06-25